Polymyalgia rheumatica is an inflammatory condition that causes severe stiffness and aching in the shoulders, neck, and hips, almost always striking people over 50. It is one of the most common inflammatory disorders in older adults, and its hallmark is a dramatic response to low-dose corticosteroids, often within days. But that quick relief comes at a cost: most people need steroids for one to three years, and the condition’s overlap with a more dangerous blood-vessel disease called giant cell arteritis makes careful monitoring essential.
Who Gets Polymyalgia Rheumatica
PMR is overwhelmingly a disease of older age. In a large population-based study in Olmsted County, Minnesota, the annual incidence was roughly 64 per 100,000 people aged 50 and over, with rates climbing steeply through the 70s before dropping off after 80.1PubMed Central. Epidemiology of Polymyalgia Rheumatica 2000-2014 and Examination of Incidence and Survival Trends over 45 Years: A Population Based Study Women are affected roughly two to three times as often as men. Geography and ancestry matter too: northern European populations have the highest rates, and evidence suggests PMR is less common in non-Caucasian populations.2PubMed. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review
If you are a woman of northern European descent in your late 60s or 70s, you sit squarely in the most common demographic. But PMR does occur in men, and it occurs in people of other backgrounds; it is just diagnosed less frequently in those groups. Whether that reflects a genuinely lower disease rate, underdiagnosis, or both remains an open question.
What PMR Feels Like
The symptoms usually arrive abruptly, sometimes over just a few days. You wake up with deep, aching pain in both shoulders that makes it hard to lift your arms. Getting out of a chair, climbing stairs, or rolling over in bed can feel nearly impossible because of severe stiffness in the hips and thighs. Morning stiffness lasting more than 45 minutes is a classic feature and sometimes the most disabling symptom. Many people also report fatigue, low-grade fevers, unintentional weight loss, and a general sense of feeling unwell.
The pain is symmetrical, meaning it tends to affect both sides of the body equally. This is one of the features doctors rely on to distinguish PMR from conditions that typically favor one side, like rotator cuff tears. Despite how much the muscles hurt, PMR is not primarily a muscle disease. The inflammation originates in the bursae, joint linings, and tendon sheaths around the shoulders and hips. Ultrasound imaging often reveals subdeltoid bursitis, biceps tenosynovitis, and hip joint effusion, and these findings on both sides strongly support the diagnosis.3Annals of the Rheumatic Diseases. US IMAGING IN THE DIAGNOSIS AND MANAGEMENT OF POLYMYALGIA RHEUMATICA
What Is Actually Going Wrong Inside
PMR is driven by a misfiring immune system, though researchers are still working out the precise trigger. The inflammation centers on the synovial tissue lining the bursae and joints around the shoulders and hips. Biopsies of inflamed bursae show macrophages, activated fibroblast-like cells, and a flood of inflammatory signaling molecules, with interleukin-6 (IL-6) playing a starring role.4PubMed. Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment IL-6 does more than inflame tissue locally. It circulates through the body, driving the production of acute-phase proteins like C-reactive protein, and it disrupts the hormonal stress-response axis in ways that contribute to the fatigue, sleep problems, and mood disturbances many patients experience.
Blood levels of IL-6 track closely with how sick patients feel, and corticosteroids suppress IL-6 production rapidly, which explains the swift symptomatic relief. However, steroids do not seem to correct whatever upstream mechanism is provoking the elevated IL-6 in the first place, which is likely why relapses are common once doses are reduced.5PubMed. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis
On the immune-cell level, PMR involves a shift in certain white blood cells. T cells skew toward inflammatory subtypes, and a subset of CD8+ T cells shows signs of premature immune aging, losing a surface marker called CD28 and gaining an enhanced tendency to release inflammatory signals.6Annals of the Rheumatic Diseases. Polymyalgia rheumatica is characterized by pro-inflammatory, senescent CD8+ T cells Whether these changes are a cause or a consequence of the disease is still being worked out. A systematic review has noted that the broader immune picture combines elements of both autoinflammation and autoimmunity, with T cells polarizing toward inflammatory profiles and the body’s normal regulatory immune responses dialing down.7PubMed. Immune system activation in polymyalgia rheumatica: Which balance between autoinflammation and autoimmunity? A systematic review
The genetic picture is murky. There is a well-known genetic link between certain immune-system genes and giant cell arteritis, but for isolated PMR, the genetic associations vary between populations and have not been consistently replicated.8PubMed Central. Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica Infections have long been suspected as triggers, since PMR sometimes seems to arrive in clusters, but a recent meta-analysis found no significant seasonal pattern in disease onset.9PubMed Central. Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature
How PMR Is Diagnosed
There is no single blood test that confirms PMR. Diagnosis is clinical, meaning it relies on a pattern of symptoms, lab results, and the exclusion of other explanations. Most doctors start with blood work showing elevated inflammatory markers, particularly erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). These are almost always raised, but not always. In one study, about 14% of confirmed PMR patients had normal ESR and CRP at diagnosis, and those patients tended to be younger and have a longer delay before being identified.10PubMed Central. Diagnostic difficulties in polymyalgia rheumatica cases with normal erythrocyte sedimentation rate and C-reactive protein values So normal blood tests do not automatically rule PMR out.
The 2012 EULAR/ACR classification criteria are the most widely used framework. They assign points based on age, shoulder and hip symptoms, morning stiffness duration, and lab values, with optional bonus points for ultrasound findings. In validation studies, these criteria reached a sensitivity above 90% and when ultrasound was added, specificity climbed significantly, from around 80% to above 90% in one European cohort.11Annals of the Rheumatic Diseases. Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study A Korean validation found a similar benefit from adding ultrasound, though overall performance was slightly lower, suggesting the criteria may work best in European populations.12PubMed. Diagnostic performance of the 2012 EULAR/ACR classification criteria for polymyalgia rheumatica in Korean patients
Ultrasound has become increasingly central to diagnosis. Bilateral subdeltoid bursitis is the most characteristic ultrasound finding, although a meta-analysis found its standalone sensitivity was only about 66%, with specificity around 89%.13Rheumatology. Imaging findings in polymyalgia rheumatica In practice, ultrasound is most useful in combination with clinical assessment rather than as a standalone test.
The Giant Cell Arteritis Connection
The overlap between PMR and giant cell arteritis (GCA) is one of the most clinically important things to understand. GCA involves inflammation of large blood vessels, especially the temporal arteries and the aorta, and it can cause permanent vision loss if untreated. The two conditions share underlying immunology and frequently coexist in the same patient. A meta-analysis estimated that about 22% of people presenting with PMR also have concurrent GCA at the time of diagnosis.14PubMed. Concurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica – A systematic review and meta-analysis
In a prospective study that screened new PMR patients with ultrasound of the large vessels, GCA was found in nearly half of them, and in about 46% of those GCA cases, the arteritis was completely silent, producing no headaches or visual symptoms and detectable only on imaging.15PubMed Central. Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica – a prospective cohort study This matters because PMR is treated with low-dose steroids, while GCA requires much higher doses. If arteritis is present but undetected, a patient on a standard PMR steroid dose could be undertreated for their vascular inflammation.
PET/CT scans can reveal vascular inflammation that ultrasound misses. In one study of 94 PET/CT scans performed on PMR patients, subclinical GCA was identified in about 11% overall, with a higher rate (roughly 14%) in patients whose PMR was not responding well to treatment.16PubMed. Usefulness of 18F-FDG PET-CT in detecting subclinical arteritis and cancer associated with polymyalgia rheumatica This is why doctors pay close attention to new headaches, jaw pain, scalp tenderness, or visual changes in anyone being treated for PMR. Any of those symptoms should be treated as urgent.
Treatment With Corticosteroids
Low-dose prednisone remains the cornerstone of PMR treatment. A systematic review found that an initial dose of 10 to 20 milligrams per day is appropriate for most patients without concurrent GCA, and symptoms typically resolve completely within a few days.17JAMA Internal Medicine. Treatment of Polymyalgia Rheumatica: A Systematic Review That rapid response is itself considered a diagnostic clue: if a patient does not improve substantially within a week of starting prednisone, the diagnosis should be questioned.
The tricky part is getting off steroids. Most guidelines recommend a slow, gradual taper over many months, and the evidence supports being patient with the process. Tapering too quickly from a low starting dose is one of the most common triggers for relapse.18PubMed. Rates of glucocorticoid taper in the management of polymyalgia rheumatica: the science behind the “art” Most people will be on some level of prednisone for at least a year, and many need it for two years or more. Relapses are common, occurring in roughly a third to half of patients at some point during the taper.
Steroid-Sparing Options
Because long-term steroids carry serious side effects, there is growing interest in medications that can reduce the total steroid burden. Methotrexate is the oldest and most studied add-on therapy. A randomized trial found that patients receiving prednisone plus methotrexate were significantly more likely to be off prednisone entirely by 76 weeks (about 88% versus 53% in the prednisone-plus-placebo group), and they had fewer flare-ups along the way.19PubMed. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial A meta-analysis confirmed methotrexate’s steroid-sparing effect, showing significantly lower cumulative steroid doses in patients who received it.20PubMed. Methotrexate for treating polymyalgia rheumatica: A meta-analysis of randomized controlled trials Methotrexate is not without its own side effects, including liver stress and lowered blood counts, so it is generally reserved for patients who relapse repeatedly or who are at high risk from prolonged steroid use.
The newer frontier is biologic drugs that target IL-6, the cytokine at the heart of PMR inflammation. Sarilumab, an IL-6 receptor blocker, was tested in a rigorous trial published in the New England Journal of Medicine. At one year, 28% of patients on sarilumab achieved sustained remission compared to 10% on placebo, and the sarilumab group needed far less total prednisone over the course of the year.21PubMed. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper Tocilizumab, another IL-6 blocker, has shown similar promise. A systematic review and meta-analysis found that tocilizumab cut relapse rates by roughly 80% and significantly lowered cumulative steroid doses.22PubMed Central. Steroid-sparing strategies in polymyalgia rheumatica: a systematic review and meta-analysis of tocilizumab with practical guidance for tapering These biologics are expensive and are typically considered for patients with relapsing or steroid-dependent disease rather than as first-line treatment.
The Bone Problem
Even at the low doses used for PMR, long-term prednisone takes a toll on bones. A study following PMR patients over 14 months found that even a mean dose of just 6 milligrams per day caused measurable bone loss at the spine, hip, and other sites, at a rate two to three times faster than normal age-related loss.23PubMed. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica Early bone loss in PMR patients tends to be concentrated in the spine and ribs, while later loss shifts to hip structures, each pattern carrying its own fracture risk. A separate study found a significant reduction in bone density at both the hip and spine after 12 months of treatment and noted that bone mass began to recover as steroid doses came down.24PubMed. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica
This is why most guidelines recommend bone-protective strategies for anyone expected to be on prednisone at 5 milligrams or more per day for three months or longer. That typically means calcium and vitamin D supplementation and, depending on your baseline fracture risk, a bisphosphonate or other osteoporosis medication. If your doctor starts you on prednisone for PMR and does not mention bone protection, bring it up yourself.
Conditions That Mimic PMR
One of the biggest challenges in diagnosing PMR is that several other conditions can look almost identical. Elderly-onset rheumatoid arthritis (EORA) is the most important mimic. Both cause symmetrical joint pain and elevated inflammatory markers in the same age group. The serum immune profiles differ somewhat: IL-6 levels tend to be higher in PMR, while another inflammatory marker called IL-1Ra tends to be higher in EORA.25Annals of the Rheumatic Diseases. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis PET/CT scanning can help distinguish the two, because PMR patients show a distinctive pattern of inflammation around tendon attachment points and bursae that is rarely seen in EORA.26PLoS ONE. Differentiation between Polymyalgia Rheumatica and Elderly-Onset Rheumatoid Arthritis Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Another common scenario involves statins. Statin medications can cause muscle pain and weakness that closely resembles PMR, and since statins are heavily prescribed in the same age group, the overlap creates genuine diagnostic confusion. One distinguishing feature is that statin-related muscle pain typically occurs without the elevated ESR and CRP seen in true PMR. Stopping the statin usually resolves symptoms within weeks to a few months, whereas PMR does not resolve on its own and generally requires steroid treatment.27Archives of Rheumatology. Is It Statin Induced Polymyalgia Rheumatica or Just a Coincidence? Shoulder and hip ultrasound can be valuable here, since the bursitis and tenosynovitis characteristic of PMR would not be expected in simple statin-related muscle complaints.28PubMed Central. If something looks like an apple, is it necessarily an apple? – reflections on so-called “statin-induced polymyalgia rheumatica”
Other conditions that can masquerade as PMR include hypothyroidism, certain cancers (particularly lymphoma and myeloma), infections like endocarditis, and late-onset lupus. A good diagnostic workup usually includes thyroid function tests, protein electrophoresis to screen for blood cancers, and sometimes additional imaging if the clinical picture does not fit neatly.
Tracking Disease Activity and Relapse
Monitoring PMR during treatment relies heavily on a combination of how you feel and what your blood tests show. ESR and CRP are the standard markers, but they are not perfect: they can remain mildly elevated for reasons unrelated to PMR, or they can be normal while the disease quietly simmers. Research into better markers has identified fibrinogen and haptoglobin as potentially useful additions. In one analysis, fibrinogen showed near-perfect ability to distinguish between active disease and remission, performing at least as well as ESR and CRP.29ACR Meeting Abstracts. Serum Markers of Disease Activity in Polymyalgia Rheumatica These markers are not yet part of routine clinical practice but may become more widely used as the evidence accumulates.
The practical reality is that managing a PMR taper is part science, part judgment. Some patients sail through a taper without trouble. Others hit a wall at 5 milligrams and flare every time they try to go lower. There is no reliable way to predict in advance who will be a “difficult taper,” which is one reason the steroid-sparing agents discussed above have generated such interest.
Quality of Life and What Recovery Looks Like
At diagnosis, people with PMR score substantially lower than the general population on measures of both physical and mental quality of life. The good news is that these scores improve markedly once treatment begins. In one study, both physical and mental quality-of-life scores rose by roughly 11 to 13 points within the first year.30PubMed. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica However, longer-term data suggests that quality-of-life scores may never fully return to the levels seen in healthy peers and can dip again after a couple of years, possibly related to steroid side effects and the burden of ongoing disease management.31Arthritis & Rheumatology. Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Physical therapy can play a meaningful supporting role. A UK survey of physiotherapists treating PMR patients found that the vast majority prescribed individualized graded exercises focused on improving shoulder movement, muscle strength, and the ability to perform daily activities.32PubMed Central. Physiotherapy for the Management of Polymyalgia Rheumatica: Results From a UK Cross‐Sectional Survey Deconditioning is a real issue in PMR, partly from the disease itself and partly from the muscle-weakening effects of steroids. Gentle, progressive exercise helps counteract both problems and supports the bone health that steroids threaten. Walking, light resistance training, and range-of-motion work for the shoulders and hips are all reasonable starting points, though any program should be adapted to how you feel day to day, especially during flares.
Statins, Infections, and Other Suspected Triggers
The question of what actually sets PMR in motion remains one of the most frustrating unknowns in rheumatology. Various infections have been proposed as triggers, including parvovirus B19, Mycoplasma pneumoniae, and Chlamydia pneumoniae, but none has been consistently linked to PMR onset. The seasonal-clustering theory, which would support an infectious trigger, has not held up under rigorous analysis.33PubMed Central. Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature Some researchers have speculated that the condition could be set off by an immune response to an infection that then fails to switch off properly, but direct proof is lacking.
The statin question keeps coming up. Because statins are so widely prescribed in the over-50 age group and because statin-related muscle symptoms can overlap with PMR, some have wondered whether statins might trigger genuine PMR. A pharmacovigilance analysis of the WHO global adverse-event database did find a signal for PMR reports in statin users, but the study acknowledged that many of those reports may have actually been statin-induced muscle problems mislabeled as PMR, since distinguishing the two is difficult without imaging.34PLoS ONE. Statin-Associated Polymyalgia Rheumatica: An Analysis Using WHO Global Individual Case Safety Database For now, there is no strong evidence that statins cause PMR as opposed to causing muscle complaints that can be confused with it. If you develop shoulder and hip pain while taking a statin, your doctor should check inflammatory markers and potentially do an ultrasound before jumping to a PMR diagnosis.